Guggenheim Capital LLC Sells 11,830 Shares of Guardant Health, Inc. (NASDAQ:GH)

Guggenheim Capital LLC lessened its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,850 shares of the company's stock after selling 11,830 shares during the quarter. Guggenheim Capital LLC owned approximately 0.09% of Guardant Health worth $3,478,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after acquiring an additional 350,606 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after acquiring an additional 29,686 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after acquiring an additional 238,037 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in shares of Guardant Health by 15.6% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after acquiring an additional 197,729 shares during the period. Finally, Norges Bank acquired a new stake in Guardant Health in the fourth quarter worth about $36,438,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GH. Raymond James reaffirmed an "outperform" rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Barclays reduced their price objective on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Piper Sandler upped their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $49.00.

Guardant Health Stock Up 3.5 %

Shares of NASDAQ:GH traded up $1.61 during trading on Thursday, reaching $47.25. 791,026 shares of the company traded hands, compared to its average volume of 2,136,235. The firm has a fifty day simple moving average of $43.39 and a 200 day simple moving average of $36.82. The firm has a market cap of $5.83 billion, a P/E ratio of -13.32 and a beta of 1.45. Guardant Health, Inc. has a 1-year low of $16.77 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.